Skip to content

Advertisement

  • Research article
  • Open Access

In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment

Contributed equally
BMC Genomics201819:640

https://doi.org/10.1186/s12864-018-5010-5

  • Received: 13 November 2017
  • Accepted: 14 August 2018
  • Published:

Abstract

Background

In the current scenario, the drug-resistant tuberculosis is a significant challenge in the control of tuberculosis worldwide. In order to investigate the in vivo evolution of drug-resistant M. tuberculosis, the present study envisaged sequencing of the draft genomes of 18 serial isolates from four pre-extensively drug-resistant (pre-XDR) tuberculosis patients for continuous genetic alterations.

Results

All of the isolates harbored single nucleotide polymorphisms (SNPs) ranging from 1303 to 1309 with M. tuberculosis H37Rv as the reference. SNPs ranged from 0 to 12 within patients. The evolution rates were higher than the reported SNPs of 0.5 in the four patients. All the isolates exhibited mutations at sites of known drug targets, while some contained mutations in uncertain drug targets including folC, proZ, and pyrG. The compensatory substitutions for rescuing these deleterious mutations during evolution were only found in RpoC I491T in one patient. Many loci with microheterogeneity showed transient mutations in different isolates. Ninety three SNPs exhibited significant association with refractory pre-XDR TB isolates.

Conclusions

Our results showed evolutionary changes in the serial genetic characteristics of the pre-XDR TB patients due to accumulation of the fixed drug-resistant related mutations, and the transient mutations under continuous antibiotics pressure over several years.

Keywords

  • Drug-resistant tuberculosis
  • Treatment
  • Genetic changes
  • SNP

Background

Tuberculosis (TB) is a chronic infectious disease. In recent years, a significant drug resistance, especially multidrug resistance (MDR) and extensive drug resistance (XDR), has occurred [1]. In 2015, there were an estimated 480,000 new cases of MDR-TB and additional 100,000 persons with rifampicin-resistant TB. Moreover, 9.7% of MDR-TB was found to have XDR-TB, which further increases the difficulty of in treating TB [2]. The effect of genetic mutations in the drug resistance of M. tuberculosis has been extensively investigated in a large amount of isolates [37]; however, the genetic alterations during the course of the long-term treatment, especially at the late stage remain to be deciphered.

The genetic mutations in M. tuberculosis after the onset of disease have been analyzed, and the results vary based on the presence or absence of the anti-TB drug treatment. The selection process resulting from the antibiotic therapy may contribute to the occurrence of SNPs. Sun et al. reported that during the treatment, the drug susceptibility of the isolates changed from sensitive strains to resistant strains, and SNPs were acquired to confer the drug resistance [8], which was further confirmed in one XDR case evolved from a susceptible ancestor [9]. However, strains isolated from patients with recurrent tuberculosis exhibited few genetic mutations (0–6 SNPs) between the primary infection and relapse [10]. This was confirmed by the results of a retrospective observational study in which the genetic changes were rarely higher than five SNPs in 3 years and the estimated rate of change in DNA sequences was 0.5 SNPs per genome per year (95% CI 0.3–0.7) in longitudinal isolates [11].

In certain SNPs, the compensatory substitutions are common in drug-resistant TB, which can rescue the deleterious mutations during evolution, and to some extent reflect the transmissibility and prevalence of drug-resistant tuberculosis in a population. With an increase in the number of sequenced isolates, more and more compensatory mutation types have been identified in M. tuberculosis [3], especially the compensatory substitutions in RpoA and RpoC for rifampicin-resistant isolates. The compensatory substitutions are also found in the clinical isolates with different genotypes, such as Beijing genotype in northern of China [12], Russia [3, 13] and LAM4/F15/KZN in South Africa [14].

The previous reports have documented the evolution of drug-resistant Mycobacterium tuberculosis in serial M. tuberculosis isolates [8, 9, 15, 16]. Recently, Andrej et al. reported a view of the heterogeneity of MTBC populations in the host lung [17], but they only focused on the first 8 weeks of treatment and most of them were not MDR. The dynamics of bacterial populations within the host during the course of treatment is not well understood. In this study, deeper characterization of the microbial dynamics within the patient for several years was done based on our results, and a number of M. tuberculosis isolates were analyzed over time.

Methods

Sample selection from patients

Four patients were recruited from Beijing Chest Hospital. Patients were selected with refractory pulmonary tuberculosis that was confirmed by the clinical symptoms and pathophysiology analysis (based on the positive pathogen cultures and image of the lung by computed tomography). The hematology and blood chemistry, urine biochemistry, mixed bacterial infection, and drug allergic reaction status were observed throughout the routine clinical work.

Eighteen tuberculosis sputum samples from the four refractory tuberculosis patients were collected during treatment through routine clinical work and re-cultured in our laboratory for genome sequencing using Middlebrook 7H9 medium added with 10% oleic acid, albumin, dextrose, and catalase (OADC) (BD, MD, USA). Those bacteria were harvested, placed in 1 mL 15% glycerol, and saved in the specimen bank.

Drug susceptibility tests

The drug susceptibility tests (DSTs) were performed using the absolute concentration method on Lowenstein-Jensen (L-J) slants. The concentration of each of the antibiotics, including isoniazid (INH), rifampin (RIF), streptomycin (SM), pyrazinamide (PZA), ethambutol (EMB), ofloxacin (OFX), capreomycin (CPM), p-aminosalicylic acid sodium (PAS), ethionamide (ETH), and amikacin (AmK) was indicated in the description [18].

Molecular typing

The bacterial genotypes were determined using a commercial kit (Isogen Bioscience BV, Maarssen, The Netherlands) according to the reported method by Kamerbeek et al. [19]. The number of tandem repeats at each locus in the isolates was determined based on the number of whole repeats in the PCR product of the size estimated from the gel. PCR for the 12 chosen loci was repeated and compared within and between gels to ensure consistent estimation of the size and tandem repeat copy number [20].

Genome sequencing and assembly

The genomic DNA of the bacteria was extracted according to the manufacturer’s guidelines (Qiagen, Beijing, China) [18]. A 500-bp paired-end library was constructed for each purified DNA sample according to the standard Illumina paired-end protocol with a low-cycle polymerase chain reaction during fragment enrichment. The sequencing was performed on the Illumina Genome Analyzer platform for either 100 or 150 cycles. The low quality reads were filtered using the DynamicTrim and LengthSort Perl scripts in SolexaQA [21]. The short reads were assembled with SOAPdenovo [22] with various length of kmer, a genome assembler developed specifically for next-generation short-read sequences, and the gaps were filled with GapCloser from SOAP after assembling.

The drug-resistant strain M. tuberculosis 11,495 was sequenced using PacBio Single-molecule real-time (SMRT) sequence technology. We used the Hierarchical Genome Assembly Process (HGAP.3) algorithm in SMRT Portal (version 2.2.0) to perform the genome assembly. After sequencing and quality-filtering, 330,992 reads were obtained with a mean length of 3905 bp totaling 1,292,425,796 bp. The complete genome sequence of M. tuberculosis 11,495 has a length of 4,428,395 bp and a G + C content of 65.6%.

Mutation detection

M. tuberculosis H37Rv is the most studied strain of tuberculosis in research laboratories. However, it is becoming apparent that use of H37Rv as a sole reference genome in analyzing clinical isolates presents some limitations in investigating M. tuberculosis [23]. Hence, we included the genome sequence of a Beijing lineage 11,495 genetically close to our strains in our analyses, in addition to H37Rv. First, the short reads were aligned with two reference genomes using the SOAP2 program [24], which included the standard reference strain M. tuberculosis H37Rv (GenBank AL123456), and the other strain 11,495. Then, SOAPsnp was used to score the SNPs from the aligned reads [25]. The SOAPsnp results were filtered as follows: (1) the read coverage of the SNP site was greater than three, (2) the Illumina quality score of each allele was greater than 30, and (3) the number of mapped best bases was more than two times the number of all mapped second-best bases. SNPs located in PE/PPE and PE-PGRS gene families that might cause incorrect read alignment were also excluded. In addition, SNPs showing sequencing and analysis noise patterns were manually removed. For deletion analysis, we used the results from the aligned reads, and the regions covered by less than three reads were considered as the deletion regions. To confirm SNPs and deletion analysis, we also performed a genome comparison analysis with results from genome assembly by Mauve [26] using default parameters. The correlation coefficient between the number of SNPs and the duration of the treatment was analyzed by the Pearson method. A p value of < 0.05 was considered statistically significant. Fisher’s exact tests [27] were used to assess the statistical significance of the difference in SNPs between our sequenced genomes and the drug-resistant reference Beijing genomes. COG annotation was performed using the BLAST software against the COG database. COG enrichment analysis was determined using Fisher’s exact test by comparing the prevalence of a target group of genes assigned to a specific COG category to the prevalence of genes in the whole genome.

Phylogenetic analysis

Maximum likelihood phylogenetic tree of the M. tuberculosis isolates was created using the SNPs of the whole genome sequences by kSNP3 with a k-mer length of 19 [28]. A median joining network can be used to infer intraspecific phylogenies where small genetic mutations are expected. It resolves all possible evolutionary paths connecting the considered taxa and postulates new nodes. Hence, a median-joining tree was created using the Population Analysis with Reticulate Trees (PopArt v1.7) [29].

Results

Characteristics of the strains

Four refractory tuberculosis patients without adjunctive surgery were included in this study. Only one patient was experiencing a first-time hospitalization; the others were re-treatment patients with a long history of tuberculosis before being hospitalized (Table 1). All of the patients exhibited more than 10% of weight loss during their hospital stay. The abnormal blood chemistry indices included alpha-hydroxybutyric acid and C-reactive protein. In addition, all patients exhibited abnormal hematology indices with higher erythrocyte sedimentation rate and fibrinogen concentration. All patients had normal urine biochemistry.
Table 1

Patient clinical data

NO.

Diagnosis

DH(y)

Weight loss(kg)

HE

Blood Chemistry

ESR

FC

ID

UB

ARD

OBI

Survival

A

IPT

45

9/64 (14.06%)

N

LAHTA, HCRP

11.37 ± 6.23

4.45 ± 1.23

No

N

RFP, PZA

AHSC, NC

YES

B

CFPT

12

8/58 (13.79%)

N

NAHBA, HCRP

21.37 ± 8.23

6.45 ± 2.23

No

N

NO

AHSC, NC

YES

C

IPT

28

17/75 (22.67%)

N

LAHBA, HCRP

35.38 ± 12

6.06 ± 1.60

No

N

NO

AHSC, NC

YES

D

IPT

0

14/58 (24.13%)

N

NAHBA, HCRP

26.67 ± 2.52

5.64 ± 1.12

No

N

NO

AHSC, NC

YES

DH(y) disease history (years), HE hematology, ESR erythrocyte sedimentation rate, FC fibrinogen concentration, ID immunodeficiency, UB urine biochemistry, ARD allergy reaction drugs, OBI other bacterial infection, IPT infiltrative pulmonary tuberculosis, CFPT chronic fibrocavenous pulmonary tuberculosis, LAHBA low alpha-hydroxybutyric acid, NAHBA normal alpha-hydroxybutyric acid, HCRP high C- reactive protein, AHSC α-hemolytic streptococcus, NC Neisser’s coccus, N normal

The implemented treatment regimens followed the WHO guidelines according to the best drug combinations and dosing schedules for multidrug resistance tuberculosis (MDR-TB) and extensive drug resistance tuberculosis (XDR-TB) [30, 31]. However, the patients were still not cured in an adequate amount of time and three of the four cases were resistant to the fourth and fifth group of the anti-TB drugs, such as ETH and PAS (Table 2). Moreover, the drug resistance patterns of the four patients increased, with the progression in treatment. Drug susceptibility tests showed that the initial strains from four patients were pre-XDR before treatment but later became XDR by the end of the study.
Table 2

Medication and drug resistance of the phenotypes and genotypes of four refractory tuberculosis patients

 

Patient A#

Patient B

Patient C

Patient D

Drug

genea

A1#

A2

A3

A4

A5

B1

B2

B3

C1

C2

C3

C4

C5

D1

D2

D3

D4

D5

H

katGa

T326 M

T326 M

T326 M

T326 M

T326 M

Y98S

Y98S

Y98S

S315 T

S315 T

S315 T

S315 T

S315 T

S315 T

S315 T

S315 T

S315 T

S315 T

inhA promotor

−15, C-T

−15, C-T

− 15,C-T

−15, C-T

− 15,C-T

   

−15, C-T

−15, C-T

− 15, C-T

−15, C-T

− 15, C-T

     

R

rpoB

H526L

H526L

H526L

H526L

H526L

H526D

H526D

H526D

D516V

D516V

N373D/ D516V

N373D/ D516V

N373D/ D516V

S531 L

S531 L

S531 L

S531 L

S531 L

Z

pncA

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T

A87T/ L120P

A87T/ L120P

A87T/ L120P

A87T/ L120P

E

embB

M306 V

M306 V

M306 V

M306 V

M306 V

Y319S

Y319S

Y319S

G406A

G406A

G406A

G406A

G406A

M306 V

M306 V

M306 V

M306 V

M306 V

Rv3806c

      

A249G

A249G

     

F140 V

F140 V

F140 V

F140 V

F140 V

Rv3756c (proZ)

G56D

G56D

G56D

G56D

G56D

             

Rv1699 (pyrG)

   

G407D

G407D

             

S

rpsL

K88R

K88R

K88R

K88R

K88R

         

K43R

K43R

K43R

K43R

rrs

     

c1402t/ a1482g

c1402t/ a1482g

c1402t/ a1482g

a514c c1402t

a514c

c1402t

a514c

c1402t

a514c

c1402t

a514c

c1402t

a1401g

a1401g

a1401g

a1401g

a1401g

LFX

gyrA

D94G

D94G

D94G

D94G

D94G

A90V

A90V

A90V

A90V

A90V/ S91P

A90V/ S91P

A90V/ S91P

A90V/ S91P

 

D94N

D94N/ A90V

D94N/ A90V

D94N/ A90V

PAS

Rv2447c (folC)

 

I43T

I43T

I43T

I43T

E153G

E153G

E153G

          

Amk

Rv2416c (eis)

   

P2L

P2L

             

MDR+

Rv1129c

P131T

P131T

P131T

P131T

P131T

P131T

P131T

P131T

D160A

D160A

D160A

D160A

D160A

P131T

P131T

P131T

P131T

P131T

CPM/Amk

Rv0323c

 

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

V215 L

LFX/ETH

Rv0404 (fadD30)

      

L10R

L10R

L10R

L10R

L10R

L10R

L10R

L10R

L10R

L10R

L10R

L10R

CPM/Amk/ LFX/ETH

Rv0565c

     

F68I

F68I

F68I

      

T402 M

T402 M

T402 M

T402 M

ETH + Amk

Rv2080 (lppJ)

     

S82a

S82a

S82a

S82a

S82a

S82a

S82a

S82a

     

ETH + Amk + CMP + S

Rv2447c (folC)

 

I43T

I43T

I43T

I43T

E153G

E153G

E153G

          

Drugs ever used

 

H R Z E

E Pa LFX PAS Amk

E Clr Pa LFX PAS Amk

E Clr Pa LFX PAS Amk

E Clr Pa LFX PAS Amk

R Z CPM LFX ETH Clr

R Z CPM LFX ETH Clr

E Clr PAS MFX Rfb

E Amk PAS ETH LFX

E Amk PAS ETH LFX

E Amk PAS ETH LFX

E Amk PZA PAS ETH LFX

E Amk PZA PAS ETH LFX

E Z Amk Clr CPM LFX

E Z Amk Clr CPM LFX

E Z S Amk Clr CFZ MFX

E Z S Amk Clr CFZ MFX

E Z S Amk Clr CFZ MFX

Resistant to

 

H R S LFX ETH

H R S LFX ETH PAS

H R S LFX ETH PAS

H R S LFX Amk ETH PAS

H R S LFX Amk ETH PAS

H R LFX ETH PAS

H R LFX ETH PAS CPM

H R E S LFX ETH PAS CPM

H R CPM

H R Lfx CPM

H R Lfx CPM

H R Lfx CPM

H R S Lfx CPM

H R LFX ETH PAS

H R LFX Amk ETH PAS

H R LFX Amk ETH PAS

H R S LFX Amk ETH PAS

H R S E Amk LFX ETH PAS CPM

H isoniazid, R rifampin, S streptomycin, Z pyrazinamide, E ethambutol, LFX levofloxacin, MFX moxifloxacin, PAS p-aminosalicylic acid sodium, Amk amikacin, ETH ethionamide, CPM capreomycin, Clr clarithromycin, CFZ Clofazimine

adrug-resistant related genes mainly based on the report by Zhang et al. [5]

#A, B, C, and D indicate the four cases, and the number following them indicates the different isolates

Molecular genotype and whole genome sequencing

PCR-based variable-number tandem repeat (VNTR) analysis was performed using the 12-MIRU-locus method and two patterns were identified, 1241 2728 3422 for isolates from patient A and 2261 2631 3321 for isolates from patients B, C and D. Both the Spoligotyping (octal codes: 000000000003771) and genome sequencing results showed that all the isolates belonged to the Beijing lineage.

The basic whole-genome sequencing statistics are shown in Additional file 1: Table S1. For each sample, 2.0 to 5.8 million 150-bp or 100-bp paired-end reads were obtained, which corresponded to an average sequencing depth ranging from 138 to 270-fold. The GC content of the genomes was approximately 65.5%, as expected for the species. The size of the genomes varied from 4.26 to 4.33 Mb.

Phylogenetic analysis of M. tuberculosis isolates

A median-joining tree was created based on the SNPs from draft genome sequences of the 18 clinical M. tuberculosis isolates and the complete genomes of four additional M. tuberbulosis strains (Fig. 1). All clinical isolates from the same patients formed separate clades, which indicated that the successive isolates were derived from the same ancestor strain.
Fig. 1
Fig. 1

Median-joining networks based on SNPs in Mycobacterium tuberculosis isolates showing microevolution events. The nodes of the networks correspond to the different MTB isolates. The color inside each circle represents the host. Each short line along the lines, linking the nodes corresponds to a single-nucleotide polymorphism (SNP) detected between the variants in the connected nodes

SNP and Indel detection

With M. tuberculosis H37Rv (ATCC 27294) as the reference, the sequencing coverage was approximately 99%, and all of the isolates harbored SNPs ranging from 1303 to 1309 (Fig. 2a, Additional file 1: Table S1). TC, AG, GA, and CT transitions were found to be the most frequent SNP types (Additional file 2: Figure S1), and the mean transversion/transition ratio was 0.60. With M. tuberculosis 11,495 as the reference, the four isolates harbored SNPs ranging from 238 to 276 (Fig. 2a).
Fig. 2
Fig. 2

SNPs of the bacterial isolates collected for each patient. a The number of SNPs was assessed relative to H37Rv (NC_000962.3) and 11,495. The number on the line indicates the number of SNPs between the two isolates. b Venn diagram of different SNPs in each patient relative to reference H37Rv

Venn diagram showing the SNPs distribution in four isolates under study compared with the H37Rv demonstrates that all the strains used in the experimentation appeared to be quite similar (Fig. 2b): 1157 SNPs were common, while each isolate possessed a few individual SNPs.

The intra-patient isolates exhibited a low SNPs variation ranging from 0 to 12 (Fig. 3a). There were 63.6% nonsynonymous, 13.6% synonymous, and 22.7% noncoding SNPs in intra-patient SNPs; while there were 54.6% nonsynonymous, 30.4% synonymous, and 15.0% noncoding SNPs when compared with H37Rv (Fig. 3b). Mutation rate is the number of SNPs between any two paired isolates per the calendar year, was calculated for each patient. The mean mutation rate was 3.2 SNP per genome per year (Fig. 3c). There was no statistically significant relationship between the treatment time and the SNP number (p < 0.05).
Fig. 3
Fig. 3

Intra-patient evolution and mutation rates. a The numbers of SNPs of the bacterial isolates at different stages of treatment for each patient. A, B, C, and D represent the four selected patients. The number on the short line indicates the numbers SNPs between two isolates at different time points of treatment of the same patient. b Pie chart depicting distribution of SNPs. Outer: patients compared with H37Rv; Inner: intra-patient. c Violin plot of calculated pairwise mutation rates per year between any pair of strains

When compared to H37Rv, some deleted genes were also identified in more than one of the tested patients (Fig. 4). cut1, plcD, and wag22 genes in all of the isolates were found to be completely deleted.
Fig. 4
Fig. 4

Comparison of the missed regions among the sequenced genomes. A circular map of the regions (Red color) missed when mapping the raw reads of the sequenced strains against the H37Rv genome (NC_000962.3). Inside track within the map displays a plot of G + C contents. In outer strain circles, from the inside out, include the following missed regions in those isolates of A1, A2, A3, A4, A5, B1, B2, B3, C1, C2, C3, C4, C5, D1, D3, D4, and D5. The circular map was constructed using Circos, which is a software package for visualizing data and information (http://circos.ca/). Genes in the main missed regions were showed (Table 3), not including those belonging to PE or PPE family that contain large, near perfect repeats that create a high likelihood of sequencing and assembly error

Mutations related to drug resistance

In this study, the nonsynonymous mutations were found in many drug target genes (Table 2). The nonsynonymous mutations related to current anti-TB drugs in katG, pncA, gyrA, rpsl, rpoB, embB, ethA, rrs, and Rv3806c were already confirmed [5, 11]. The nonsynonymous mutations in katG, rpoB, pncA, embB, and gyrA were found in all of the 18 isolates, and drug-resistance related mutations in rpsl, rrs, ethA, Rv3806c and inhA promoter were found in the isolates from certain patients. No mutation was found in rpsA and panD for PZA resistance, in ribD and thyA for PAS resistance, in gidB for SM or Amk resistance, in embA, embC, embR, iniAC for EMB resistance, and in ahpC, fabG1 and inhA for INH resistance (Table 2). Some nonsynonymous mutations that were inferred for drug resistance [32] were also found in part among the isolates, such as Rv2447c (folC), Rv3756c (proZ), Rv1699 (pyrG), Rv1129c, Rv0323c, Rv0404 (fadD30), Rv0565c, Rv2080 (lppJ) and Rv3862c (whiB6). We analyzed the occurrence of compensatory substitutions in RpoA and RpoC in all the sequenced 18 isolates and found that the compensatory substitutions exist only in RpoC at I491T, in isolates from patient D.

Transient mutation

Apart from the fixed mutations that were related to the drug resistance, several transient mutations was also found in all of the patients (Additional file 3: Table S2). A micro-heterogeneity at some related genome sites of the isolates was found on further examination of the transient mutations based on the raw reads. Interestingly, the same base positions that determined this microheterogeneity were also found in the isolates from different patients.

Next, we investigated all the nonsynonymous SNPs to identify the mutations that could be involved in infection and persistence in all patients. The isolates in patient A harbored a P2L mutation in eis (Rv2416c) which shows to enhance the intracellular survival of M. tuberculosis [33, 34]. In patient C, we found a C451Y mutation in ponA2 (Rv3682), which is involved in the adaptation of M. tuberculosis to dormancy [35].

Confirmation of the SNPs and Indels with published data

We downloaded all the raw read sequences reported in China [5] from NCBI’s Sequence Read Archive (SRA) by SRA Toolkit and performed de novo genome assembly for all samples by SOAPdenovo [22] with various length of kmer. In order to find the specific SNPs of the tested isolates with Beijing genotypes in China, their draft genome sequences were compared to the reference drug-resistant strains. The phylogenetic trees demonstrated that the tested 18 bacterial isolates are evolutionarily close (Fig. 5). Ninety three SNPs exhibited significantly different percentages (adjusted p-value< 0.01) between our sequenced genomes and the reference drug-resistant Beijing genomes (Additional file 4: Table S3). Interestingly, we found two nonsense mutations, 1 coding sequence substitution c. 397G > T mutation occurred in Rv0768 (aldA) and one c. 245C > A mutation occurred in Rv2080 (lppJ).
Fig. 5
Fig. 5

Microevolution of the tested refractory TB population. Maximum likelihood phylogenetic trees of the M. tuberculosis drug-resistant isolates were created using the SNPs of the whole genome sequences by kSNP3 with a k-mer length of 19. The red branch includes all of our sequenced refractory TB strains

We further analyzed the distribution of SNPs according to the different categories of the Clusters of Orthologous Groups (COG). Secondary metabolites biosynthesis, transport, and catabolism (class Q), Lipid transport and metabolism (class I), and Energy production and conversion (class C) were the most frequent COG categories (Additional file 5: Figure S2). In addition, we found that they were significantly enriched in Secondary metabolites biosynthesis, transport, and catabolism (class Q; P value = 0.048).

In order to confirm the deletions, these results were compared to the reported genome sequences in China [5]. Almost all of the three genes (cut1, plcD, and wag22) were partially deleted in all of the Beijing genotype isolates, and in few of the non-Beijing genotype isolates. There was no difference in the frequency of deletion of genes among the drug-resistant and drug-sensitive isolates. The deletions appeared to be the marker of Beijing genotype rather than being the cause of a long-term TB history.

Discussion

Drug-resistant tuberculosis is a serious threat to public health worldwide. The varied genetic mutations in M. tuberculosis after its onset depend on the microenvironment in which the tuberculosis bacilli exist. The selection process resulting from the antibiotic therapy may be one of the main reasons for the occurrence of SNPs. The occurrence of SNPs in the genomes from the patients in whom the drug susceptibility changed from sensitive to resistant strains is well known [8, 9]. Recent studies involving re-sequencing of a large number of clinical isolates have also provided important insights into the complex evolution patterns of the TB pathogen [3, 4, 36, 37]. This study further confirmed the genetic changes when the isolates in pre-XDR patients were treated with more complex regimens in an attempt to explain the prolonged histories of some tuberculosis patients (Table 2).

The genomic changes of the isolates within the individuals were significantly different. Only a few mutations, were found between baseline and re-infection, and there were no different sites between the baseline and relapse strains in 82% relapse cases [10]. In longitudinal isolates from 30 individuals and 25 families, the estimated rate of change in DNA sequences was 0.5 SNPs, per genome, per year (95% Confidence interval 0.3–0.7), with the divergence rarely higher than five SNPs in 3 years [11]. However, Ford et al. suggested that the rate of change in DNA sequences is a constant of 0.5 SNP per genome per year in latent, active, or re-activated disease over the same period of time [38]. In this study, the mean mutation rate was 3.2 SNP per genome per year (Fig. 3c). This indicates that the complex treatments might increase the genetic changes including the compensatory substitutions and the non-coding regions (Fig. 3b). Furthermore, based on the previous reports, we found that the SNPs of each isolate ranged from 1300 to 1500 bases [10, 39], while the SNPs among the strains with Beijing genotypes range from 200 to 500 bases [5, 19]. The SNPs of the intra-isolates were about 22.4 bases at the early sensitive stage [10].

Transient mutations were reported early in a case that evolved from a susceptible ancestor to XDR-TB [9]. The genetic loci, in this case, were not stable and changed their priority of bases under the antibiotic circumstance [9], implying the microheterogeneity in the cultured sputum population. In this study, many loci with microheterogeneity were found in the genome of the isolates at each time point and were repeatedly found in the isolates from different patients. The transient mutations were observed higher in the nonsynonymous (63.6%) and non-coding regions (22.7%) in intra-patient than that compared with H37Rv, with 54.6% nonsynonymous and 15.0% non-coding SNPs (Fig. 3b). The transient mutations suggest that the unstable genetic sites exist in the M. tuberculosis genome with the probability of a strong positive selection under the pressure of antibiotics.

The compensatory substitutions are common in drug-resistant TB that reflects to some extent the transmissibility and prevalence of drug-resistant tuberculosis in a population. With an increase in the number of sequenced isolates, more and more compensatory mutation types were observed in M. tuberculosis [3, 13, 40, 41]. For rifampicin-resistant isolates, the occurrence of compensatory substitutions in RpoA and RpoC were frequently found in isolates carrying the rpoB S450 L mutation (equivalent to Escherichia coli S531 L) [3, 13, 40, 42]. In this study, compensatory substitutions were only found in RpoC (I491T) in the isolates from patient D.

A large number of mutations related to the drug resistance have been found worldwide. In this study, the isolates from four pre-XDR patients had mutations in genes like katG and inhA promoter for INH, rpoB for RIF, rrs and eis for Amk/CPM, and gyrA for LFX [5, 37]. Some other mutations related to the resistance of EMB (embB, Rv3806c, proZ, pyrG), PZA (pncA), and PAS (folC) were also found in some of the isolates, with the genotype in keeping with the phenotype (Table 2). In addition, some genes related to the multidrug resistance were listed in Table 2, such as Rv3756c (proZ), Rv1699 (pyrG), Rv1129c, Rv0323c, Rv0404 (fadD30), Rv0565c and Rv2080 (lppJ), which need to be further verified by molecular and biochemical methods.

In this study, we tried to find the characteristics of the SNPs and Indels specific to the four refractory pre-XDR TB patients, in comparison with the not refractory pre-XDR TB published data [5]. The phylogenetic tree demonstrated that the isolates in this study are phylogenetically close to each other (Fig. 5), indicating that the SNPs found in the refractory 18 tuberculosis isolates were potentially specific, of which 93 SNPs exhibited significantly different percentages (Additional file 4: Table S3). Although the main deletions in cut1 [43], plcD, and wag22 occurred in all of the M. tuberculosis populations, our data showed negative results, indicating that these deletions were specific for drug-resistant isolates, and they might be characteristics of the Beijing lineage (Table 3).
Table 3

Comparison of the deleted genes that occurred in the Beijing genotype and the non-Beijing genotype isolates

Gene namea

Gene length (bp)

Beijing genotype (n, %)

Non- Beijing Genotype (n, %)

Resistant (n = 91, %)

Sensitive (n = 21)

Resistant (n = 26)

Sensitive (n = 23)

cut1

525

91, 100

20, 95.24

13, 50.00

14, 60.87

plcD

843

90, 98.91

20, 95.24

4, 15.38

7, 30.43

wag22

2745

78, 85.71

21, 100

21, 80.77

16, 69.56

#The genome sequence of Mycobacterium tuberculosis H37Rv (NC_000962.3) was used as reference

aDeletion occurred in all of the populations in all three genes

Conclusions

In summary, four pre-XDR tuberculosis cases were enrolled in this study to test the whole genome changes of the 18 serial isolates from these patients during the elaborate treatment. The results indicate that each patient with a long history of TB is not infected by mixed strains (pathogen population). The SNPs found by whole genome sequencing showed transient and fixed mutations. Mutations related to the drug-resistance were fixed under the continuous drug pressure. We also found a transient mutation in some cases, suggesting that the treatment regimen could eradicate some bacterial population at different stages, except for the mutations related to the drug resistance. Of all the SNPs and Indels, 93 SNPs exhibited significantly different percentages in this study. These results indicate that the genetic changes might be partly responsible for refractory pre-XDR TB in the four selected TB cases.

Notes

Abbreviations

Amk: 

Amikacin

COG: 

Clusters of Orthologous Groups

CPM: 

Capreomycin

DSTs: 

Drug susceptibility tests

EMB: 

Ethambutol

ETH: 

Ethionamide

INH: 

Isoniazid

LFX: 

Levofloxacin

MDR: 

Multidrug resistance

OFX: 

Ofloxacin

PAS: 

p-aminosalicylic acid sodium

PZA: 

Pyrazinamide

RIF: 

Rifampin

SM: 

Streptomycin

SNPs: 

Single nucleotide polymorphisms

TB: 

Tuberculosis

VNTR: 

Variable-number tandem repeat

XDR: 

Extensive drug resistance

Declarations

Acknowledgements

The authors would also like to acknowledge the Beijing Bio-Bank of Clinical Resources-Tuberculosis, BBCR-Tuberculosis (D131100005313012) at Beijing Chest Hospital for providing all of the type isolates and clinical isolates used in this study.

Funding

The work was supported by the Key Project Specialized for Infectious Diseases of the Chinese Ministry of Health (2013ZX10003009), Tongzhou District Science and Technology Committee (KJ2017CX053), and the National Natural Science Foundation of China (NSFC) (31601081 and 81871691).

Availability of data and materials

The raw sequencing data of M. tuberculosis isolates reported in this study have been deposited in GenBank under accession numbers SRR3742653-SRR3742670.

Authors’ contributions

ZS and BZ conceived and designed the experiments. YX, SC, and ZS collected the clinical isolates and analyzed the clinical information and experimental data. YX, and JW conducted the drug-resistance tests. FL and YH performed the genome sequencing, and data analysis. FL, ZS, YX, JW, and SC wrote the manuscript. FL, YH, ZS, and BZ discussed the results and critiqued the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The ethical committee of Beijing Chest Hospital approved this study. The study methodologies conformed to the standards set by the Declaration of Helsinki and the experiments were undertaken with the understanding and written consent of each patient. All the authors ensured that all risks were minimized and the subjects were not injured.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Chinese Materia medica, China Academy of Chinese Medical Science, Beijing, 100700, China
(2)
National Tuberculosis Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China
(3)
CAS key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Science, Beijing, 100101, China
(4)
Beijing Key Laboratory in Drug Resistant Tuberculosis Research, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, China

References

  1. WHO: Global Tuberculosis Report 2016 http://www.who.int/tb/publications/global_report/en/. 2016.
  2. Falzon D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, Lienhardt C, Jaramillo E, Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49Google Scholar
  3. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014;46:279–86.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15:1193–202.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, Liu Z, Li C, Galwey N, Deng J, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet. 2013;45:1255–60.View ArticlePubMedGoogle Scholar
  6. Lieberman TD, Wilson D, Misra R, Xiong LL, Moodley P, Cohen T, Kishony R. Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis. Nat Med. 2016;22:1470–4.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Homke R, Ritter C, et al. Acquired resistance to Bedaquiline and Delamanid in therapy for tuberculosis. N Engl J Med. 2015;373:1986–8.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Sun G, Luo T, Yang C, Dong X, Li J, Zhu Y, Zheng H, Tian W, Wang S, Barry CE 3rd, et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis. 2012;206:1724–33.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Eldholm V, Norheim G, von der Lippe B, Kinander W, Dahle UR, Caugant DA, Mannsaker T, Mengshoel AT, Dyrhol-Riise AM, Balloux F. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol. 2014;15:490.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH, van Helden P, Pym A, Mahayiddin AA, Chuchottaworn C, Sanne IM, et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med. 2013;1:786–92.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, Eyre DW, Wilson DJ, Hawkey PM, Crook DW, et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis. 2013;13:137–46.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Li QJ, Jiao WW, Yin QQ, Xu F, Li JQ, Sun L, Xiao J, Li YJ, Mokrousov I, Huang HR, Shen AD. Compensatory mutations of rifampin resistance are associated with transmission of multidrug-resistant Mycobacterium tuberculosis Beijing genotype strains in China. Antimicrob Agents Chemother. 2016;60:2807–12.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley SD, Parkhill J, Nejentsev S, Hoffner SE, et al. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res. 2012;22:735–45.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Reeves AZ, Campbell PJ, Willby MJ, Posey JE. Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:444–9.View ArticlePubMedGoogle Scholar
  15. Perez-Lago L, Comas I, Navarro Y, Gonzalez-Candelas F, Herranz M, Bouza E, Garcia-de-Viedma D. Whole genome sequencing analysis of intrapatient microevolution in Mycobacterium tuberculosis: potential impact on the inference of tuberculosis transmission. J Infect Dis. 2014;209:98–108.View ArticlePubMedGoogle Scholar
  16. McGrath M, Gey van Pittius NC, van Helden PD, Warren RM, Warner DF. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69:292–302.View ArticlePubMedGoogle Scholar
  17. Trauner A, Liu Q, Via LE, Liu X, Ruan X, Liang L, Shi H, Chen Y, Wang Z, Liang R, et al. The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy. Genome Biol. 2017;18:71.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, Liu Y, Nie L, Guo A, Li C. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol. 2008;46:4075–7.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–14.PubMedPubMed CentralGoogle Scholar
  20. Sun Z, Li W, Xu S, Huang H. The discovery, function and development of the variable number tandem repeats in different Mycobacterium species. Crit Rev Microbiol. 2016;42:738–58.PubMedGoogle Scholar
  21. Cox MP, Peterson DA, Biggs PJ. SolexaQA: at-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinform. 2010;11:485.View ArticleGoogle Scholar
  22. Luo R, Liu B, Xie Y, Li Z, Huang W, Yuan J, He G, Chen Y, Pan Q, Liu Y, et al. SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. Gigascience. 2012;1:18.View ArticlePubMedPubMed CentralGoogle Scholar
  23. O'Toole RF, Gautam SS. Limitations of the Mycobacterium tuberculosis reference genome H37Rv in the detection of virulence-related loci. Genomics. 2017;109:471–4.View ArticlePubMedGoogle Scholar
  24. Li R, Yu C, Li Y, Lam TW, Yiu SM, Kristiansen K, Wang J. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics. 2009;25:1966–7.View ArticlePubMedGoogle Scholar
  25. Li R, Li Y, Fang X, Yang H, Wang J, Kristiansen K, Wang J. SNP detection for massively parallel whole-genome resequencing. Genome Res. 2009;19:1124–32.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Darling AC, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 2004;14:1394–403.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Fisher RA. On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soc. 1922;85:87–94.View ArticleGoogle Scholar
  28. Gardner SN, Slezak T, Hall BG. kSNP3.0: SNP detection and phylogenetic analysis of genomes without genome alignment or reference genome. Bioinformatics. 2015;31:2877–8.View ArticlePubMedGoogle Scholar
  29. Bandelt HJ, Forster P, Rohl A. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol. 1999;16:37–48.View ArticlePubMedGoogle Scholar
  30. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621–9.View ArticlePubMedGoogle Scholar
  31. WHO. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. In: Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Geneva, WHO Guidelines Approved by the Guidelines Review Committee; 2014.Google Scholar
  32. Cronan JE Jr, Waldrop GL. Multi-subunit acetyl-CoA carboxylases. Prog Lipid Res. 2002;41:407–35.View ArticlePubMedGoogle Scholar
  33. Kim KH, An DR, Song J, Yoon JY, Kim HS, Yoon HJ, Im HN, Kim J, Kim DJ, Lee SJ, et al. Mycobacterium tuberculosis Eis protein initiates suppression of host immune responses by acetylation of DUSP16/MKP-7. Proc Natl Acad Sci U S A. 2012;109:7729–34.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Wei J, Dahl JL, Moulder JW, Roberts EA, O'Gaora P, Young DB, Friedman RL. Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages. J Bacteriol. 2000;182:377–84.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Calvanese L, Falcigno L, Maglione C, Marasco D, Ruggiero A, Squeglia F, Berisio R, D'Auria G. Structural and binding properties of the PASTA domain of PonA2, a key penicillin binding protein from Mycobacterium tuberculosis. Biopolymers. 2014;101:712–9.View ArticlePubMedGoogle Scholar
  36. Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, Blum MG, Rusch-Gerdes S, Mokrousov I, Aleksic E, et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet. 2015;47:242–9.View ArticlePubMedGoogle Scholar
  37. Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J, Consortium TBGG, Chapman SB, Cho SN, et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat Genet. 2017;49:395–402.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet. 2011;43:482–6.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Liu F, Hu Y, Wang Q, Li HM, Gao GF, Liu CH, Zhu B. Comparative genomic analysis of Mycobacterium tuberculosis clinical isolates. BMC Genomics. 2014;15:469.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2011;44:106–10.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE 3rd, Stover CK. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science. 1996;272:1641–3.View ArticlePubMedGoogle Scholar
  42. Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, et al. Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Med. 2015;12:e1001880.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Parker SK, Curtin KM, Vasil ML. Purification and characterization of mycobacterial phospholipase a: an activity associated with mycobacterial cutinase. J Bacteriol. 2007;189:4153–60.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement